<DOC>
	<DOCNO>NCT01280266</DOCNO>
	<brief_summary>The prevalence Raynaud phenomenon ( RP ) , reversible vaso-constriction skin discoloration , 5-10 % general population . Often conventional measure warm minimize exposure cold enough many patient require treatment vasodilator therapy . A recent study show good efficacy safety profile sildenafil , selective inhibitor cGMP specific phosphodiesterase type 5 ( PDE5 ) RP . Here , investigator aim examine efficacy safety Udenafil , new PDE5 inhibitor , compare amlodipine , well know calcium channel blocker , treatment secondary RP Korean patient .</brief_summary>
	<brief_title>Efficacy Study PDE-5 Inhibitor Calcium Channel Inhibitor Treatment Secondary Raynaud Phenomenon</brief_title>
	<detailed_description />
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>secondary Raynaud 's phenomenon primary raynaud phenomenon active infection hypersensitivity PDE5 inhibitor Calcium Chanel Blocker ( CCB ) elevate AST/ALT ( 3 time upper normal limit ) severe renal failure patient nitrite nitric oxide ( NO ) donor treatment recent history cerebrovascular accident , acute myocardial infarction , coronary artery bypass surgery hypotension ( le 90/50 mmHg ) uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Pathological Conditions</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Blood circulation</keyword>
</DOC>